Your browser doesn't support javascript.
loading
Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
Blumenfeld, Andrew M; Boinpally, Ramesh; De Abreu Ferreira, Rosa; Trugman, Joel M; Dabruzzo, Brett; Ailani, Jessica; Lipton, Richard B.
Affiliation
  • Blumenfeld AM; Headache Center of Southern California, Carlsbad, California, USA.
  • Boinpally R; Clinical Pharmacology, AbbVie Inc., Madison, New Jersey, USA.
  • De Abreu Ferreira R; Clinical Pharmacology, AbbVie Inc., Madison, New Jersey, USA.
  • Trugman JM; Clinical Pharmacology, AbbVie Inc., Madison, New Jersey, USA.
  • Dabruzzo B; Clinical Pharmacology, AbbVie Inc., Madison, New Jersey, USA.
  • Ailani J; MedStar Georgetown University Hospital, Washington, District of Columbia, USA.
  • Lipton RB; The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
Headache ; 63(3): 322-332, 2023 03.
Article in En | MEDLINE | ID: mdl-36602199
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Calcitonin Gene-Related Peptide Receptor Antagonists / Migraine Disorders Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Humans Language: En Journal: Headache Year: 2023 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Calcitonin Gene-Related Peptide Receptor Antagonists / Migraine Disorders Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Humans Language: En Journal: Headache Year: 2023 Type: Article Affiliation country: United States